These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23503513)

  • 1. Cancer vaccination at older age.
    Gravekamp C
    Interdiscip Top Gerontol; 2013; 38():28-37. PubMed ID: 23503513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging and cancer vaccines.
    Gravekamp C; Chandra D
    Crit Rev Oncog; 2013; 18(6):585-95. PubMed ID: 24579737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of aging on cancer vaccination.
    Gravekamp C
    Curr Opin Immunol; 2011 Aug; 23(4):555-60. PubMed ID: 21763118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is cancer vaccination feasible at older age?
    Gravekamp C; Jahangir A
    Exp Gerontol; 2014 Jun; 54():138-44. PubMed ID: 24509231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
    Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
    Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
    Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
    Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate immune cells in the tumor microenvironment.
    Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
    Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate immune mediators in cancer: between defense and resistance.
    Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
    Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
    Galati D; Zanotta S
    Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
    Anari F; Ramamurthy C; Zibelman M
    Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
    Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.
    Tang YC; Thoman M; Linton PJ; Deisseroth A
    Cancer Immunol Immunother; 2009 Dec; 58(12):1949-57. PubMed ID: 19444444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-33 in Malignancies: Friends or Foes?
    Shen JX; Liu J; Zhang GJ
    Front Immunol; 2018; 9():3051. PubMed ID: 30619376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy.
    Dar TB; Henson RM; Shiao SL
    Front Immunol; 2018; 9():3077. PubMed ID: 30692991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
    Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
    Front Immunol; 2020; 11():990. PubMed ID: 32536918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic Targeting of Cancer Stem Cells.
    Zhang J; Li Q; Chang AE
    Surg Oncol Clin N Am; 2019 Jul; 28(3):431-445. PubMed ID: 31079798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunology of aging and cancer development.
    Fulop T; Larbi A; Kotb R; Pawelec G
    Interdiscip Top Gerontol; 2013; 38():38-48. PubMed ID: 23503514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
    Zhang S; Zhao J; Bai X; Handley M; Shan F
    Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.